Featured Articles

1. Why Pharma Needs More Physicians And How To Get There 10/30/2026

   Physicians can broaden their patient impact in pharma, but they need better exposure to industry career paths, writes physician-scientist Emmanuelle Clerisme-Beaty, M.D.

2. An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs? 10/28/2026

   FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?

3. An Express Lane To Clinical Testing? FDA's Expedited IND Pilot Program 10/27/2026

   FDA’s Expedited IND pilot pairs developers with expert advisers and uses rolling submissions to improve IND quality and accelerate Phase 1 trials, writes Luke Nguyen.

4. MFN Cuts Manufacturer Prices, But Savings Still Face A Longer Journey 10/23/2026

   MFN cuts manufacturer drug prices, but transparency across PBMs and pharmacies is needed to ensure the savings reach patients, writes Paul Pruitt.

5. A 250 Million Patient Blind Spot: Why Pharma Ignored Lymphatic Medicine 10/21/2026

   Once overlooked as the merely the human body’s plumbing, the lymphatic system is emerging as a new therapeutic frontier, writes Celltaxis CEO Eileen Heffernan.

6. The Bond Factor: Resilience Through Change 10/15/2026

   In her third and final installment of the Bond Factor leadership series, Wanda Shoer offers advice for navigating work and professional changes effectively.

7. The Future Of Life Sciences Supply Chain Distribution 10/13/2026

   Life sciences distribution is shifting toward AI-powered, resilient networks that improve speed, efficiency, compliance, and patient care, according to experts at EY. 

8. Stop Planning For The Year You Think You're Going To Have 10/9/2026

   Life sciences leaders should plan for multiple futures and adapt their strategies as new evidence arrives, writes Jason C. Bork. 

9. What Thirty Years Of EBVST Teaches Us About Off-The-Shelf Cell Therapy 10/7/2026

   After 30 years of use in transplant medicine, EBV-specific T cells offer key lessons for safer, scalable allogeneic cell therapies, writes Ivan Horak, M.D.

10. The Case For Reciprocal Due Diligence In Life Sciences Board Recruitment 10/1/2026

    Candidates for seats on company boards should scrutinize governance, culture, and leadership dynamics before saying yes, writes DeeDee DeMan.